Results 121 to 130 of about 6,034 (173)

Paradoxical Progressive Multifocal Leukoencephalopathy With Immune Reconstitution Inflammatory Syndrome in a Patient With AIDS: A Case Report. [PDF]

Cureus
Ibrahim IA, Lopez P, Sivapalan V.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Maraviroc: a new CCR5 antagonist

Expert Review of Anti-Infective Therapy, 2009
Maraviroc is a small molecule and a member of a new class of antiretroviral compounds known as CCR5 antagonists, which block R5-tropic HIV entry into CD4 cells. HIV entry into the cell requires binding to a CD4 molecule and, in the majority of cases, to a coreceptor, either chemokine coreceptor 4 (CXCR4) or 5 (CCR5). In August 2007, the US FDA approved
Shilpa, Sayana, Homayoon, Khanlou
exaly   +3 more sources

Maraviroc

Drugs of Today, 2007
Maraviroc, first in a new pharmacological class of antiretroviral agents known as CCR5 antagonists, has been approved by the U.S. Food and Drug Administration for the treatment of HIV-infected adult patients who are infected with only CCR5-tropic HIV-1 virus and who have HIV-1 strains resistant to multiple antiretroviral agents.
Hind, Fadel, Zelalem, Temesgen
  +9 more sources

Maraviroc: Pharmacokinetics and drug Interactions

Antiviral Therapy, 2009
Maraviroc is a potent selective CCR5 antagonist and is the first of this new class of oral agents to be approved for the treatment of CCR5-tropic HIV type-1. Maraviroc is extensively metabolized by CYP3A4, with renal clearance accounting for approximately 23% of total clearance. The half-life of maraviroc is approximately 16 h.
Samantha, Abel, David J, Back, Manoli, Vourvahis   +2 more
openaire   +2 more sources

Pharmacocinétique clinique du maraviroc Clinical pharmacokinetic of maraviroc

Médecine et Maladies Infectieuses, 2008
Maraviroc (MVC, UK-427,857) is the first member of a new class, the CCR5 antagonists. By an original mechanism of action, maraviroc binds to the CCR5 receptor in order to prevent HIV from binding and entering human cells. Maraviroc (Celsentri) is an orally administered drug available as 150 and 300 mg film-coated tablets.
openaire   +2 more sources

Maraviroc exposure is influenced by exogenous thyrotoxicosis

AIDS, 2021
Maraviroc (MVC) is a noncompetitive antagonist of CCR5 that inhibits HIV replication in treatment-experienced and treatment-naïve patients. MVC is considered to be safe and is part of the HIV armamentarium.MVC is a substrate of CYP3A4/5 and P-gp, which account for most of MVC pharmacokinetic variability related to drug–drug interactions (DDI).
Metsu, David, Aquilina, Christian, Delobel, Pierre, Gandia, Peggy, Savagner, Frédérique, Raymond, Stéphanie, Caron, Philippe, Martin-Blondel, Guillaume   +7 more
openaire   +3 more sources

CCR5-Maraviroc Structure

Science Signaling, 2013
The crystal structure of the HIV co-receptor CCR5 bound to the HIV drug maraviroc provides insight into how HIV enters cells.
openaire   +2 more sources

Maraviroc: A Ccr5 Antagonist

Future HIV Therapy, 2008
HIV requires binding to both the CD4 molecule and a coreceptor to enable entry into the cell. CCR5 is a chemokine receptor that is utilized as a coreceptor by the majority of virus in early asymptomatic HIV infection. Maraviroc is a novel small molecule CCR5 antagonist which, in Phase IIb/III clinical trials up to 48 weeks, has been shown to be ...
LKK Tan, M Nelson
openaire   +1 more source

Lessons from maraviroc clinical trials

Expert Review of Anti-infective Therapy, 2011
Evaluation of: Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359, 1429-1441 (2008). Maraviroc is the first commercially available HIV chemokine receptor antagonist targeting HIV that utilizes the CCR5 chemokine receptor (R5 tropic).
Paolo, Troia-Cancio, David M, Asmuth
openaire   +2 more sources